Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-08-28

FDA Approved: DIHYDROERGOTAMINE MESYLATE — Supplemental Application (Provepharm Inc.)

View source ↗

Summary

FDA approved a supplemental application for dihydroergotamine mesylate from Provepharm Inc. under ANDA212046.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dihydroergotamine mesylate (Dihydroergotamine Mesylate)

Snippet

SUPPL AP for DIHYDROERGOTAMINE MESYLATE (DIHYDROERGOTAMINE MESYLATE)